tretinoin and Bronchial-Neoplasms

We previously reported that all-trans-retinoic acid (RA) treatment can prevent in vitro transformation of immortalized human bronchial epithelial (HBE) cells.. To determine whether methylation inhibits RARbeta expression in HBE cells, we used sodium bisulfite sequencing to compare RARbeta P2 promoter methylation patterns in RA-sensitive (BEAS-2B) and RA-resistant (BEAS-2B-R1) HBE cells. Immunoblotting was used to assess induction of the RARbeta, placental transforming growth factor beta (PTGF-beta), Fos-related antigen 1 (Fra-1), and transglutaminase II (TGase II) proteins by RA following treatment with azacitidine, a DNA demethylating agent. The expression, transcriptional activity, and growth suppressive activity of RARbeta1', a novel RAR isoform, were evaluated in lung cancer cells transfected with RARbeta1', and expression was also studied in paired normal lung tissues and lung tumors. All statistical tests were two-sided.. Hypermethylation was observed in the 3' region of the RARbeta P2 promoter of BEAS-2B-R1 but not BEAS-2B cells. Azacitidine treatment of BEAS-2B-R1 cells restored RA-inducible RARbeta2 and PTGF-beta expression but not that of RARbeta1', Fra-1, or TGase II. RARbeta1' expression was repressed in RA-resistant BEAS-2B-R1 cells and in lung cancers, compared with adjacent normal lung tissues. BEAS-2B-R1 cells transiently transfected with RARbeta1' had increased RA-dependent activation of a retinoic acid receptor element (RARE)-containing reporter plasmid compared with vector control (mean = 3.2, 95% confidence interval [CI] = 3.1 to 3.3 versus mean = 1.4, 95% CI = 1.3 to 1.5; P<.001). In H358 lung cancer cells transiently transfected with RARbeta1', RA treatment restored target gene expression compared with that in vector-transfected cells and suppressed cell growth compared with that in untreated cells (4 microM; treated mean = 0.49 versus untreated mean = 1.0, difference = 0.51, 95% CI = 0.35 to 0.67, P = .003; 8 microM: treated mean = 0.50 versus untreated mean = 1.0, difference = 0.50, 95% CI = 0.26 to 0.74, P = .015).. Restoration of RARbeta1' expression may overcome retinoid resistance in lung carcinogenesis.

Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Morphogenetic Proteins; Bronchial Neoplasms; Cell Line, Tumor; DNA Methylation; Gene Expression Regulation, Neoplastic; Growth Differentiation Factor 15; GTP-Binding Proteins; Humans; Immunoblotting; Luciferases; Lung Neoplasms; Membrane Proteins; Promoter Regions, Genetic; Protein Glutamine gamma Glutamyltransferase 2; Protein Isoforms; Proto-Oncogene Proteins c-fos; Receptors, Retinoic Acid; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic; Transfection; Transglutaminases; Tretinoin

Using an in vitro lung carcinogenesis model consisting of normal, premalignant, and malignant human bronchial epithelial (HBE) cells, we analyzed the growth inhibitory effects of 26 novel synthetic retinoic acid receptor (RAR)- and retinoid X receptor (RXR)-selective retinoids. RAR-selective retinoids such as CD271, CD437, CD2325, and SR11364 showed potent activity in inhibiting the growth of either normal or premalignant and malignant HBE cells (IC50s mostly <1 microM) and were much more potent than RXR-selective retinoids. Nonetheless, the combination of RAR- and RXR-selective retinoids exhibited additive effects in HBE cells. As the HBE cells became progressively more malignant, they exhibited decreased or lost sensitivity to many retinoids. The activity of the RAR-selective retinoids, with the exception of the most potent retinoid, CD437, could be suppressed by an RAR panantagonist. These results suggest that: (a) RAR/RXR heterodimers play an important role in mediating the growth inhibitory effects of most retinoids in HBE cells; (b) CD437 may act through an RAR-independent pathway; (c) some of the RAR-selective retinoids may have the potential to be used in the clinic as chemopreventive and chemotherapeutic agents for lung cancer; and (d) early stages of lung carcinogenesis may be responsive targets for chemoprevention by retinoids, as opposed to later stages.

Topics: Antineoplastic Agents; Bronchi; Bronchial Neoplasms; Cell Division; Chemoprevention; Drug Resistance, Neoplasm; Epithelial Cells; Humans; Lung Neoplasms; Precancerous Conditions; Receptors, Retinoic Acid; Retinoids; Tretinoin

The capability of ascorbic acid (AA) and transretinoic acid (RA) to interfere with 3H-benzo(a)pyrene [B(a)P] binding to DNA has been evaluated in cultured bronchial mucosa explants from patients with bronchial cancer. The results show that the DNA-bound 3H-B(a)P is smaller in treated cultures than in controls. To explain this finding, it is proposed that AA, acting as antioxidant, inhibits the oxidative degradation of B(a)P, and that RA, a lipophilic compound interacting with the lipid components of mixed function oxidases, could modify the activities of these enzymes. Both vitamins decrease the concentration of ultimate carcinogen metabolites, which can interact with DNA. Furthermore, the treatment with RA does not increase DNA synthesis, while AA inhibits 3H-thymidine incorporation.

Topics: Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Benzo(a)pyrene; Bronchi; Bronchial Neoplasms; Cell Division; DNA; Drug Synergism; Humans; Organ Culture Techniques; Thymidine; Tretinoin

Animal studies have shown. a) an association between vitamin A and cancers of epithelial origin, and b) that vitamin A and its analogues delay tumour appearance, retard tumour growth and regress tumours induced by carcinogenic polycyclic aromatic hydrocarbons. Human epidemiological and biochemical studies suggest that cancers of epithelial origin may be associated with vitamin A deficiency. Vitamin A and its analogues may have a prophylactic and a therapeutic role in cancers of epithelial origin.

Topics: Animals; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Humans; Lung Neoplasms; Mouth Neoplasms; Neoplasms, Experimental; Pharyngeal Neoplasms; Tretinoin; Vitamin A; Vitamin A Deficiency